Navigation Links
Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
Date:12/7/2008

cardiovascular conditions, or cardiovascular death.

The incidence of major and clinically relevant non-major bleeding events was significantly higher in the 30 mg and 60 mg twice-daily DU-176b regimens than it was in patients given warfarin (7.8 percent, 10.6 percent and 3.2 percent, respectively). In contrast, the incidence of major and clinically relevant non major bleeding events with the 30 and 60 mg once-daily DU-176b regimens was comparable to that with warfarin (3.0 percent, 3.8 percent, and 3.2 percent, respectively). There were no significant differences in patients with elevated liver enzymes or bilirubin across all treatment groups, and there were no significant differences in the rates of secondary endpoints.

Once-Daily Oral Rivaroxaban Compared WithSubcutaneous EnoxaparinEvery 12 Hours for Thromboprophylaxis After Total KneeReplacement: RECORD4

[Abstract #35]

Alexander G.G. Turpie, MD, McMaster University, Hamilton, Ontario, Canada

This study concluded that investigational rivaroxaban, an oral Factor Xa inhibitor, is more efficacious than a current standard of therapy, enoxaparin, for the prevention of venous thromboembolism following total knee replacement surgery without significantly increasing the risk of bleeding. Coupled with previous research that demonstrated that post-operative rivaroxaban was more effective than pre-operative enoxaparin in preventing deep-vein clotting, along with an easier method of administration (oral versus subcutaneous injection), this study may change the way physicians prevent serious blood clots in patients undergoing major orthopedic surgery.

In this study, a total of 3,148 patients were randomized to receive either once-daily oral rivaroxaban (10 mg) star
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... France , Dec. 19, 2014  Eli Lilly ... (Euronext Paris: FR0011184241 – ADOC) today announced a worldwide ... as BioChaperone Lispro, for treatment in people with type ... Adocia,s proprietary BioChaperone® technology and is currently in Phase ... BioChaperone Lispro with the goal of optimizing glucose levels ...
(Date:12/17/2014)... DIEGO , Dec. 17, 2014 Royal ... Volcano Corporation (NASDAQ: VOLC ), a global leader ... announced that they have entered into a definitive merger agreement. ... to acquire all of the issued and outstanding shares of ... purchase price of USD 1 billion (approx. EUR 800 million), ...
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2
... Cellular Dynamics International (CDI) ... Endothelial Cells for use in vascular-targeted drug discovery, ... Endothelial cells make up the lining of blood ... research across a multitude of disease states.  Endothelial dysfunction ...
... Eli Lilly and Company (NYSE: LLY ... of FORTEO® (teriparatide [rDNA origin] injection) and zoledronic acid ... remodeling in transiliac crest bone biopsies from postmenopausal women ... presentation at the 2011 Annual Meeting of the American ...
Cached Medicine Technology:Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery 2Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery 3Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery 4New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid 2New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid 3New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid 4New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid 5New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid 6New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid 7
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again ... provide logistics and support for one of Dallas’ largest holiday ... history of giving back to the community in which it ... Drive were Whataburger® and 99.5 The Wolf. , There is ... gifts to children who would otherwise not receive any is ...
(Date:12/22/2014)... The NLN’s 2015 Leadership Institute ... month. Faculty have been selected through competitive application ... for administrative leadership roles within their academic institutions; ... Educators, featuring a curriculum uniquely devised for up-and-comers ... , Twenty nurse educators were chosen for the ...
(Date:12/21/2014)... 22, 2014 Weddingshe.com, an outstanding online ... has recently released its new selection of Cocktail Dresses ... made according to the newest fashion trends. ... dresses for cocktail parties . All of them are ... off. We are making every effort to offer a ...
(Date:12/21/2014)... New York (PRWEB) December 21, 2014 ... and other product liability claims involving a class ... mimetics continue to move forward in a federal ... Southern District of California, Bernstein Liebhard LLP reports. ... Court has established a data cut-off date of ...
(Date:12/21/2014)... December 21, 2014 Serious Buyer, Andrew ... 1967 Jm Morrison and the Doors International Ballroom at ... would also be the only time that Morrison's mother ... on Nov. 25, 1967. According to Hawley, “This would ... did play the Alexandria Roller Rink earlier that year ...
Breaking Medicine News(10 mins):Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4
... Prime Healthcare Services,("Prime Healthcare"), has acquired ... Center from Tenet Healthcare Corporation,("Tenet") effective June ... Encino Hospital,Medical Center. Prime Healthcare also has ... additional Tenet hospitals in California --,167-bed Garden ...
... LONDON, June 2 , - Misys Trade ... Misys plc (FTSE: MSY.L), the global application ... been awarded the double accolade of,winning two SWIFTReady ... solutions., Having been the first trade services ...
... Bunk bed-related injuries are not an issue of ... a study conducted by investigators at the Center for ... Nationwide Childrens Hospital. The study, published in the June ... who sustain bunk bed-related injuries are younger than 10 ...
... baseball-related injuries has decreased within the last 10 years, ... to a new study conducted by researchers at the ... Research Institute at Nationwide Children,s Hospital. During the two-year ... occurred with an injury rate of more than one ...
... medical center, new channel hosted exclusively by doctors, available 24/7 to listeners ... ... ... Radio, features daily shows and reports on general health and, wellness, plastic surgery, ...
... into the toxins, virulence, spread and prevention of the ... issue of the Journal of Medical Microbiology. These findings ... ammunition in the fight against a sometimes deadly pathogen. ... is most common in hospitals. It can cause a ...
Cached Medicine News:Health News:Prime Healthcare Services to Acquire Three Hospitals from Tenet Healthcare Corporation 2Health News:Misys Wins Prestigious Gold Labels From SWIFT for Entire Trade Services Solutions Portfolio 2Health News:Bunk beds pose dangers to kids and adults 2Health News:Bunk beds pose dangers to kids and adults 3Health News:Injuries to high school baseball players becoming more serious 2Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 2Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 3Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 4Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 5Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 6Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 7Health News:SIRIUS Satellite Radio & NYU Langone Medical Center Launch 'Doctor Radio' Channel 8Health News:Advances in C. difficile research 2
The advanced optics of Frequency 55 Aspheric offer an unsurpassed level of visual quality. By focusing light to a common focal point on the back of eye, instead of a general area, the aspheric design...
The proven daily wear spherical soft contact lens....
Surevue brand contact lenses deliver exceptional overall performance in a contact lens since they're easy to use and offer great comfort....
An easy-to-fit high water content spherical soft lens manufactured using cast molding technology, and designed for use in the correction of myopia on a daily wear or extended wear basis....
Medicine Products: